The Growing Role of Neoadjuvant Immunotherapy in MIBC

Roger Li, MD, of the H. Lee Moffitt Cancer Center and Research Institute, describes the background context, design, and intended outcome of his recent study comparing the effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive bladder cancer (MIBC).

Dr. Li first explains how the evolution of previous research related to immunotherapy and MIBC influenced the design of his study, then explains more about how patients were sampled, categorized, and assessed over the course of the trial.

View his further comments on the Event-Free Survival Benefit of Neoadjuvant Immunotherapy in MIBC.